8 Amendments of Dan-Ştefan MOTREANU related to 2024/2030(DEC)
Amendment 18 #
Draft opinion
Paragraph 3
Paragraph 3
3. Welcomes the continued development of the One Health Framework and the creation of the One Health Task Force to strengthen collaboration with EMA, EFSA, EEA and ECHA; highlights the importance of ensuring good and fair cooperation between the Agencies and increased collaboration with Member States;
Amendment 21 #
Draft opinion
Paragraph 4 a (new)
Paragraph 4 a (new)
4 a. Acknowledges the lessons learnt during the COVID-19 pandemic, calling for the need for pandemic preparedness and a unified EU response strategy, that utilises digital early warning systems for prompt and efficient decision making.
Amendment 42 #
Draft opinion
Paragraph 7
Paragraph 7
7. Notes with concern the difficulty to recruit sufficient experts from Member States to the ECHA’s Scientific Committees, posing a risk to the ECHA’s ability to meet legal deadlines and targets in regulatory processes that are dependent on the Committees’ outputs, in particular in the light of increasing tasks being attributed to the ECHA; identifies a need for increased localised collaboration with universities, research centers and specialised national services from the Member States;
Amendment 52 #
Draft opinion
Paragraph 3
Paragraph 3
3. Notes that the EEA is tasked with tracking progress towards the 8th Environment Action programme (‘8th EAP’), which builds on the European Green Deal and sets the framework for Union environmental policy until 2030, with a long-term priority objective for 2050 of living well within planetary boundaries, while investing in competitiveness as outlined in the Draghi report; welcomes the release of its first annual monitoring report in December 2023, on the basis of a set of 28 headline indicators and corresponding targets such as climate change mitigation and adaptation, circular economy and biodiversity;
Amendment 62 #
Draft opinion
Paragraph 6
Paragraph 6
6. Takes note with concern that despite the multi-year nature of the EEA’s tasks, an imbalance exists concerning the numbers of permanent versus contractual posts, as well as operational staff versus support staff, leading to a constant need for reskilling as well as an overload of administrative work for scientists; considers that taking into account the substantial increase of workload, and in order to properly perform the tasks on the Union’s goals for, inter alia, climate neutrality, circular economy and nature restoration, the EEA’s staff number should continue to substantially grow in the years to coreflect the scope and extent of its demanding work programme.
Amendment 70 #
Draft opinion
Paragraph 3
Paragraph 3
3. Notes that the EFSA closed 660 scientific questions in 2023, slightly below the target of 673 but better than the result achieved since 2020; highlights the need to decrease the amount of questions in stock; welcomes the measures put in please to increase the speed of the Risk Assessment process; proposes the establishment of an expedited assessment track for urgent health concerns and response mechanisms for discrepancies between Union standards and trade obligations, to reduce backlog and respond to trade obligations;
Amendment 92 #
Draft opinion
Paragraph 2
Paragraph 2
2. Notes that in 2023, the EMA recommended for marketing authorisation 77 new human medicines, including 39 new active substances, and 14 new veterinary medicines, including 9 new active substances; welcomes the fact that the EMA confirmed seventeen orphan- status designations under the Union framework for orphan medicines, the purpose of which is to encourage the development and marketing of medicines for patients with rare diseases, adopting an expedited mechanism under special conditions;
Amendment 104 #
Draft opinion
Paragraph 6 b (new)
Paragraph 6 b (new)
6 b. Recommends the establishment of a formal framework for joint procurement of essential medicines across Member States, modelled on the success of the COVID-19 vaccine procurement process, for ensuring equitable access to high- quality medicines through economies of scale.